Haematology: DLBCL: consolidation radiotherapy for bulky disease (UNFOLDER)
Free question published 14 November 2026
A 47-year-old man with stage II diffuse large B-cell lymphoma has a bulky mediastinal mass measuring 9 cm at diagnosis. He completes six cycles of R-CHOP-21 and his end-of-treatment PET-CT shows a complete metabolic response. His treatment follows the UNFOLDER trial design. Based on UNFOLDER, what does omitting consolidation radiotherapy to the original bulk do to his outcome?
- AIt mandates two further cycles of R-CHOP instead
- BIt is non-inferior, therefore radiotherapy can always be safely and routinely omitted after R-CHOP for bulky disease
- CIt significantly worsens event-free survival, which led to early closure of the no-radiotherapy arms
- DIt significantly improves overall survival by avoiding radiotherapy toxicity
- EIt has no measurable effect because PET complete response abolishes any benefit of radiotherapy
Why C is correct
In the UNFOLDER trial of aggressive B-cell lymphoma with bulky (7.5 cm or greater) or extralymphatic disease, a planned interim analysis found significantly better event-free survival in the radiotherapy arm, leading to predefined closure of the observation (no-radiotherapy) arms; 3-year EFS was 84% with radiotherapy versus 68% without. Consolidation radiotherapy to bulk after R-CHOP improved event-free survival.
And why the others are not
- AIncorrect: UNFOLDER compared radiotherapy with observation, not additional R-CHOP cycles.
- BIncorrect: UNFOLDER did not show non-inferiority of omission; the arms omitting radiotherapy were stopped for excess failures.
- DIncorrect: omitting radiotherapy did not improve overall survival; it worsened event-free survival.
- EIncorrect: in this trial radiotherapy to bulk still improved event-free survival, so the effect was not abolished.
Source UNFOLDER - consolidation radiotherapy to bulky disease in aggressive B-cell lymphoma — Held G, Thurner L, et al. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study (DSHNHL/GLA). Hemasphere. 2023;7(7):e904.
More free haematology questions
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing